50242-125Level 3
Columvi (Glofitamab)
**Product type:** Human Prescription Drug
**Active ingredient:** GLOFITAMAB
**Strength:** 2.5 mg/2.5mL
**Dosage form:** Solution, Concentrate
**Route:** Intravenous
**Labeler:** Genentech, Inc.
**Marketing category:** BLA (BLA761309)
**Pharmacologic class:** Bispecific CD20-directed CD3 T Cell Engager [EPC], CD20-directed Antibody Interactions [MoA], CD3 Receptor Agonists [MoA], CD3-directed Antibody Interactions [MoA], Cytochrome P450 Inhibitors [MoA], Increased Cytokine Activity [PE]
GET
/api/v1/systems/ndc_fda/nodes/50242-125Hierarchy Explorer
Loading...
Cross-system equivalences0
No cross-system equivalences mapped for this node.